Pfizer raises US prices for more than 100 drugs
London
PFIZER Inc, which plans a US$160 billion merger with Ireland-based Allergan Plc to slash its US tax bill, on Jan 1 raised US prices for more than 100 of its drugs, some by as much as 20 per cent, according to statistics compiled by global information services company Wolters Kluwer.
Pfizer confirmed a 9.4 per cent increase for heavily advertised pain drug Lyrica, which generated US$2.3 billion in 2014 US sales; a 12.9 per cent increase for erectile dysfunction drug Viagra, which had 2014 US sales of US$1.1 billion; and a 5 per cent increase for Ibrance, a novel breast cancer drug launched last year at a list price of US$9,850 per month, or US$118,200 per year.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Holiday Inn owner IHG’s Q1 revenue up 2.6%, leisure travel demand remains strong
WSJ moves Asia headquarters from Hong Kong to Singapore
South Korea to slap fines on food suppliers for ‘shrinkflation’
Olam outbids Dreyfus’ sweetened deal for Australia’s Namoi, raises offer to A$0.66 per share
Live Nation’s revenue beats estimates as boom in concerts drive ticket sales
Jim Beam owner bets on canned vodka cocktails to double revenue